The Latest Cardiac and Vascular News
Sanifit to start new clinical development program of SNF472 in End Stage Kidney Disease patients with Peripheral Artery Disease FDA has agreed to key aspects of the clinical program, including the primary endpoint for the single pivotal phase 3 study There are approximately 175,000 and 150,000 ESKD patients with PAD […]
Dr. Flanagan, an accomplished chemist and formulation specialist, leads manufacturing and clinical development of JanOne’s PAD candidate TV1001SR LAS VEGAS, June 25, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs with non-addictive pain relieving properties, continues to build […]
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. announced that it has enrolled the first two patients in ACTIVATE I, a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to open vessels and keep them open without the use […]
Houston, TX, May 20, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — AngioSoma Inc. (OTC: SOAN) (“AngioSoma” or the “Company”) is pleased to announce that the Company’s peripheral arterial disease (“PAD”) product, Atherectomy Catheter II, is a catheter-based platform capable of treating a broad range of plaque types, including calcified plaque and addresses many […]
XARELTO® has the potential to be the first anticoagulant in 20 years(i) to show a benefit in these high-risk patients Two major Phase 3 trials have evaluated XARELTO® vascular dose plus aspirin in treating patients with atherosclerotic disease RARITAN, N.J., March 28, 2020 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & […]
JanOne’s lead drug clinical candidate TV1001SR to treat PAD and associated pain will be manufactured by CoreRX Pharma with phase 2b trials expected to begin Q4 2020 LAS VEGAS, Feb. 6, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ: JAN), a company focused on bringing treatments to market for conditions that cause severe pain and drugs […]
Dr. Christopher Kevil, pioneer in nitrite based PAD treatment and Dr. Amol Soin, foremost expert is neuropathic pain, provide scientific insight on the pain relieving qualities of JanOne’s lead drug candidate Interview to be distributed nationally on all 193 Sinclair broadcasting network affiliate stations in 89 markets across the nation […]
Kevil brings global scientific expertise to advance JanOne’s drug development portfolio and advise on upcoming Phase 2b clinical trials for PAD LAS VEGAS, Jan. 16, 2020 /PRNewswire/ — JanOne Inc. (NASDAQ:JAN) appoints Christopher Kevil, Ph.D., a pioneer in nitrite based PAD treatment, to lead its scientific advisory board. In this role, Dr. Kevil will […]
Dr. Milton Leon is opening the San Angelo Cardiovascular Center of Excellence to bring quality care, cost savings, and convenience to the area SAN ANGELO, Texas, Jan. 13, 2020 /PRNewswire/ — San Angelo is getting its first outpatient catheterization lab, bringing a new level of convenience, cost savings, and state-of-the art care to […]
SALT LAKE CITY–(BUSINESS WIRE)–Alucent Biomedical Inc. has received U.S. Food and Drug Administration approval to proceed with a Phase 1 clinical trial to evaluate the safety and efficacy of its revolutionary Natural Vascular Scaffolding (NVS) technology. The therapy is designed to treat peripheral artery disease (PAD) of the lower extremities, a […]
